- AU$47.27m
- AU$42.83m
- AU$32.33m
Brief: Cyclopharm Reports FY Net Loss Attributable A$13.2 Mln
Australia's Cyclopharm falls on wider HY loss
Brief: Cyclopharm Says Co Signs US National Agreement With HCA For Technegas
Australia's Cyclopharm soars on diagnostic tech deployment contract
Australia's Cyclopharm hits near 3-month high on US supply agreement
Brief: Cyclopharm Ltd Enters Into Interim Agreement To Supply Veterans Health Administration
Brief: Cyclopharm Posts HY Net Loss Before Tax A$7.48 Million
Australia's Cyclopharm jumps on US pass-through tag for lung imaging tech
Brief: Cyclopharm Says Technegas Awarded US Pass-Through Reimbursement Status
Brief: Cyclopharm Announces Institutional Placement To Raise A$20 Million At A$1.42 Per New Share
Brief: Cyclopharm Says Coding Determination For Technegas Received From Center For Medicare Medicaid Services
Brief: Cyclopharm Says FY Group Revenue Up 29.0%
Brief: Cyclopharm Appoints Jason Smith As CFO
Brief: Cyclopharm Reports FY Unaudited Revenue A$28.9 Million Up 14%
Australia's Cyclopharm rises on US FDA approval for lung treatment product
Brief: Cyclopharm Signs First USA Contract For Technegas
Australia's Cyclopharm gains on FDA approval for lung disease diagnostic agent
Brief: Cyclopharm Updates On Technegas USA Commercialisation
Brief: Cyclopharm Receives USFDA Approval For Technegas